

30 January 2017

Company Announcements Office
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

INFORMATION REQUIRED UNDER ASX LISTING RULE 3.10.5A

Further to the Appendix 3B lodged on 30 January 2017 for the issue of 9,230,770 fully paid ordinary shares (**Placement**), Cynata Therapeutics Limited (ASX: CYP) provides the following information required under ASX Listing Rule 3.10.5A:

- (a) The dilutive effect of the Placement on existing shareholders is as follows:

Number of Shares on issue prior to the Placement: 80,826,478

Placement issue under Listing Rule 7.1 (1,956,963 shares)	
Placement issue under Listing Rule 7.1A (7,273,807 shares)	
Total dilution as a result of the Placement	10.25%


Number of Shares on issue following the Placement: 90,057,248

Details of the approximate percentage of the issued capital following the completion of the Placement held by pre-Placement shareholders and new shareholders are as follows. Please note this information is in relation to the total shares issued under the Placement, as we are not able to separately identify shareholders pertaining to the 7,273,807 shares issued under Listing Rule 7.1A:

Pre-Placement shareholders who did not participate in the Placement	88.86%
Pre-Placement shareholders who did participate in the Placement	11.14%
Participants in the Placement who were previously not shareholders	73.83%

- (b) The Company issued the shares as a placement under Listing Rule 7.1A as it believed that this was the most efficient mechanism for raising funds at the time as it gives the Company certainty of raising the amount of capital required to expand the development of the Company's proprietary Cymerus™ therapeutic mesenchymal stem cell technology.
- (c) No underwriting arrangements were in place for the Placement; and
- (d) The commission for the Placement is 6% of the total funds raised

Yours faithfully



Peter Webse
Company Secretary